Transcriptional regulation by mutant p53 and oncogenesis

Sub-Cellular Biochemistry

Volumn 85, Issue , 2014, Pages 91-103

  Santoro, Raffaela ^a   Strano, Sabrina ^a   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; Mutant p53; Mutation; Target; Transcription

Indexed keywords

PROTEIN P53;

CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

CARCINOGENESIS; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922391998     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-9211-0_5     Document Type: Article

References (88)

1. Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26: 7773-7779.
2. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G et al (2003) Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14: 406-413.
3. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
4. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS (2003) Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23: 5556-5571.
5. Bykov VJ, Issaeva N, Selivanova G, Wiman KG (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23: 2011-2018.
6. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
7. Cofflll CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF et al (2012) Mutant p53 interactome identifles nardilysin as a p53R273H-speciflc binding partner that promotes invasion. EMBO Rep 13: 638-644.
8. Deb S, Jackson CT, Subler MA, Martin DW (1992) Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66: 6164-6170.
9. Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M et al (2011) ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS 15: 305-312.
10. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202.
11. Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G (2008) The disruption of the protein complex mutant p53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 7: 3440-3447.
12. Di Como CJ, Gaiddon C, Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19: 1438-1449.
13. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al (1993) Gain of function mutations in p53. Nat Genet 4: 42-46.
14. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V et al (2012) Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26: 830-845.
15. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831-841.
16. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al (2012). Mutant p53 gainof-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32: 3286-3295.
17. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19: 1038-1048.
18. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
19. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F et al (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16: 1086-1093.
20. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510.
21. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP (1998) Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18: 3735-3743.
22. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV et al (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 99: 937-942.
23. Friedler A, Veprintsev DB, Hansson LO, Fersht AR (2003) Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem 278: 24108-24112.
24. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887.
25. Goeman F, Fontemaggi G, Blandino G (2012) ChIP-on-chip to identify mutant p53 targets. Methods Mol Biol 962: 211-226.
26. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G (2010) Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 285: 14160-14169.
27. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deflcient mice. Nat Genet 5: 225-229.
28. Haupt S, Haupt Y (2004) Improving cancer therapy through p53 management. Cell Cycle 3: 912-916.
29. Haupt S, Haupt Y (2012) Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption. Cell Cycle 11: 217-218.
30. Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R et al (2002) P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing highdose chemotherapy with autologous blood stem cell support. Int J Cancer 100: 290-296.
31. Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer. Toxicol Lett 102-103: 219-225.
32. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr (2003) Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
33. Iwakuma T, Lozano G, Flores ER (2005) Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 4: 865-867.
34. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
35. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100: 8424-8429.
36. Kim E, Deppert W (2004) Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 93: 878-886.
37. Koga H, Deppert W (2000) Identiflcation of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo. Oncogene 19: 4178-4183.
38. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A 105: 6302-6307.
39. Lane DP, Hupp TR (2003) Drug discovery and p53. Drug Discov Today 8: 347-355.
40. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
41. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U et al (2012) Targetingp53 in vivo: afirst-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30: 3633-3639.
42. Liu G, McDonnell TJ, Montes de Oca Luna R, Luna R, Kapoor M, Mims B, El-Naggar AK et al (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97: 4174-4179.
43. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE et al (1996) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16: 6009-6019.
44. Luu Y, Bush J, Cheung KJ Jr, Li G (2002) The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 276: 214-222.
45. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M et al (2006) Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 17: 1504-1511.
46. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efflcacy of p53 restoration in tumors. Cell 127: 1323-1334.
47. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S et al (2013). Gain of function mutp53 down-regulates miR223 contributing to chemoresistance of cultured tumor cells. Oncogene 33: 1601-1608.
48. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
49. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A et al (2011) Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2: 1203-1217.
50. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB et al (2012) Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 32: 2992-3000.
51. O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL (2004) Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 64: 8199-8207.
52. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
53. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al (2006) The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
54. Pastorcic M, Das HK (2000) Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene. J Biol Chem 275: 34938-34945.
55. Preuss U, Kreutzfeld R, Scheidtmann KH (2000) Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation. Int J Cancer 88: 162-171.
56. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21: 2119-2129.
57. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367.
58. Sankala H, Vaughan C, Wang J, Deb S, Graves PR (2011) Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys 512: 52-60.
59. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A et al (2004) Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23: 4430-4443.
60. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF et al (2004) Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 64: 7447-7454.
61. Shivakumar CV, Brown DR, Deb S, Deb SP (1995) Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15: 6785-6793.
62. Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldflnger N, Rotter V (2012) Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 125: 3144-3152.
63. Song H, Xu Y (2007) Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 6: 1570-1573.
64. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
65. Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331: 834-842.
66. Soussi T, Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312.
67. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277: 18817-18826.
68. Strano S, Blandino G (2003) p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle 2: 348-349.
69. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219.
70. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD et al (2000) Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 275: 11327-11332.
71. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS (2002) The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1: 47-55.
72. Tang Y, Luo J, Zhang W, Gu W (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839.
73. Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE et al (2005) Proflling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65: 375-389.
74. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E et al (2012) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10: 4330-4340.
75. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
76. Vaughan C, Windle B, Deb S (2013) ChIP sequencing to identify p53 targets. Methods Mol Biol 962: 227-236.
77. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
78. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldflnger N, Oren M et al (2004) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64: 8318-8327.
79. Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26: 2202-2211.
80. Will K, Warnecke G, Wiesmuller L, Deppert W (1998) Speciflc interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for baseunpairing. Proc Natl Acad Sci U S A 95: 13681-13686.
81. Wu J, Smith LT, Plass C, Huang TH (2006) ChIP-chip comes of age for genome-wide functional analysis. Cancer Res 66: 6899-6902.
82. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP (2002) Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 277: 47976-47979.
83. Xu Y (2003) Regulation of p53 responses by post-translational modiflcations. Cell Death Differ 10: 400-403.
84. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
85. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG et al (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33: 442-451.
86. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.
87. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M (2006) Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25: 359-369.
88. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G et al (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849-853.